# A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

> **NCT02747004** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 234 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Tamoxifen
- **DRUG:** Prophylactic Loperamide

## Key facts

- **NCT ID:** NCT02747004
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-14
- **Primary completion:** 2018-06-15
- **Final completion:** 2026-12
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02747004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02747004, "A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02747004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*